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Abstract
A recently identified breast cancer-associated mutation in the metalloprotease ADAM12 alters a potential dileucine
trafficking signal, which could affect protein processing and cellular localization. ADAM12 belongs to the group of A
Disintegrin And Metalloproteases (ADAMs), which are typically membrane-associated proteins involved in ectodomain
shedding, cell-adhesion, and signaling. ADAM12 as well as several members of the ADAM family are over-expressed in
various cancers, correlating with disease stage. Three breast cancer-associated somatic mutations were previously identified
in ADAM12, and two of these, one in the metalloprotease domain and another in the disintegrin domain, were investigated
and found to result in protein misfolding, retention in the secretory pathway, and failure of zymogen maturation. The third
mutation, p.L792F in the ADAM12 cytoplasmic tail, was not investigated, but is potentially significant given its location
within a di-leucine motif, which is recognized as a potential cellular trafficking signal. The present study was motivated both
by the potential relevance of this documented mutation to cancer, as well as for determining the role of the di-leucine motif
in ADAM12 trafficking. Expression of ADAM12 p.L792F in mammalian cells demonstrated quantitatively similar expression
levels and zymogen maturation as wild-type (WT) ADAM12, as well as comparable cellular localizations. A cell surface
biotinylation assay demonstrated that cell surface levels of ADAM12 WT and ADAM12 p.L792F were similar and that
internalization of the mutant occurred at the same rate and extent as for ADAM12 WT. Moreover, functional analysis
revealed no differences in cell proliferation or ectodomain shedding of epidermal growth factor (EGF), a known ADAM12
substrate between WT and mutant ADAM12. These data suggest that the ADAM12 p.L792F mutation is unlikely to be a
driver (cancer causing)-mutation in breast cancer.
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Introduction
ADAM12 is a member of the ADAMs (A Disintegrin And
Metalloproteases) family of transmembrane zinc-dependent pro-
teases with a characteristic domain structure (Fig. 1). ADAMs are
involved in regulating integrin-mediated cell adhesion, cell
signaling and the proteolytic release, known as ectodomain
shedding of cell surface-associated substrates [1–4]. Several
members of the ADAM family are highly expressed in a variety
of human carcinomas, likely contributing to tumor development
and/or progression through the release of epidermal growth factor
receptor EGFR ligands or effects on cell-cell or cell-matrix
adhesion [1,3]. We, and others previously showed that ADAM12
expression was markedly upregulated in different cancers [5–9],
and that the level of ADAM12 in urine from breast and bladder
cancer patients correlated with disease status and stage [10,11].
ADAM12 promotes tumor progression in transgenic mouse
models of breast and prostate cancer [6,12,13] and several
ADAMs are considered as promising targets for cancer therapy
[14–16]. Despite accumulating evidence for involvement of
ADAMs in cancer, only a few cancer-related ADAM mutations
have been reported (see ref. [17] for complete list). Human
ADAM12 exists in two naturally occurring splice variants;
ADAM12-L resembling the prototypical transmembrane ADAM
protein shown in figure 1 and ADAM12-S, a soluble splice variant,
lacking the transmembrane domain and the cytoplasmic tail. In an
analysis of genomic changes in breast cancer, three somatic
heterozygous mutations were found in ADAM12, p.D301H in the
metalloprotease domain, p.G479E in the disintegrin domain, and
p.L792F in the cytoplasmic domain (Fig. 1) [18]. Bioinformatic
analysis predicted that only p.D301H and p.G479E, but not
p.L792F were likely to be cancer-causing, since no changes were
tolerated at these two positions [19]. Analysis of the p.D301H and
p.G479E proteins strongly suggested misfolding of these mutants,
since neither was secreted, both were retained in the endoplasmic
reticulum (ER), and neither underwent zymogen maturation, a
process mediated by furin that converts nascent 120-kDa
ADAM12 to the mature 90-kDa form and occurs downstream
of the ER [19]. The p.L792F mutation is situated in the second
(from the N-terminus) of two di-leucine motifs in ADAM12.
Although the p.L792F mutation was predicted to be inconsequen-
tial, it is of potential interest as it affects a di-leucine motif that is an
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37628important sorting signal in internalization and/or trafficking of
several proteins (Fig. 1). Di-leucine motifs play critical roles in the
sorting of many type I, type II, and multi-spanning transmem-
brane proteins, by associating with adaptor proteins, such as AP-
complexes or Golgi-localized, c-ear containing, ADP-ribosylation
factor-binding proteins (GGAs) [20,21].
We therefore sought to investigate if the p.L792F mutation in
the cytoplasmic domain of ADAM12 (since only ADAM12-L is
affected, the nomenclature ADAM12 is used for the sake of
simplicity) altered protein processing, trafficking and internaliza-
tion with potential functional implications for cell proliferation and
protein ectodomain shedding. Rigorous analysis suggested that the
ADAM12 p.L792F mutant was comparable to WT ADAM12 in
every aspects analyzed, indicating that the di-leucine motif was not
involved in the intracellular trafficking of ADAM12 and thus may
not be contributing significantly to the breast cancer phenotype.
Results and Discussion
The ADAM12 wild-type and p.L792F mutant are similarly
expressed and processed
To evaluate expression and processing of ADAM12 p.L792F,
we initially expressed ADAM12 WT and ADAM12 p.L792F
mutant in 293VnR cells, which in contrast to many other cell lines
readily express human full-length ADAM12 protein. ADAM12
p.L792F was expressed at the same levels as ADAM12 WT and,
contrary to what has been described for the other two ADAM12
mutants [19], there was no difference in zymogen processing
between WT and ADAM12 p.L792F (Fig. 2A). The similar
molecular masses of the two major forms also suggested that there
was no alteration of glycosylation. To assess if the two proteins
exhibit similar intracellular localization, 293VnR cells transiently
expressing WT or ADAM12 p.L792F were analyzed by immuno-
fluorescence and confocal microscopy. Fixed and permeabilized
cells were stained with the anti-ADAM12 monoclonal antibody
6E6. WT and mutant ADAM12 constructs had similar transfec-
tion efficiency and were expressed at similar levels. Both proteins
localized to punctate intracellular organelles located in the
perinuclear region (Fig. 2B left-hand images) and were also
localized to cell-cell contacts (Fig. 2B right-hand images),
indicating similar steady-state cellular distribution of the two
proteins. Furthermore, when GFP-tagged ADAM12 WT was
expressed in the same cell as a myc-tagged ADAM12 p.L792F there
was complete co-localization of the two tags (Fig. 2C). This finding
is in marked contrast to the two other cancer-associated mutations
(p.D301H and p.G479E), which resulted in intracellular retention
[19]. In many cases mutations in di-leucine trafficking motifs have
severe consequences [20], EGFR being one example, where
substitution of either of its two di-leucine motifs alters expression
[22] and internalization [23]. However, our findings demonstrate
that mutating the ADAM12 di-leucine motif had no obvious effect
on expression level, processing, or overall cellular localization of
the protein.
ADAM12 p.L792F is internalized at the same level and
rate as wild-type ADAM12
Since the di-leucine motif could facilitate endocytosis from the
cell surface [20,21], we compared the internalization of WT and
ADAM12 p.L792F. A cell surface biotinylation assay, using
cleavable biotin was used to determine the amounts of internalized
protein. In this assay, cell surface-associated biotin, which has not
been internalized, can be removed by washing with reducing
agent. Transiently transfected 293VnR cells expressing ADAM12
WT or the p.L792F mutant were biotinylated at 4uC and proteins
were allowed to be internalized for 30 or 60 min at 37uC. Total
cell surface levels of either WT ADAM12 or ADAM12 p.L792F
were determined in cells kept at 4uC and not treated with reducing
agent. While some variability in the amount of cell surface protein
was observed, quantitative analysis of independent replicate
experiments did not disclose any difference in the total amount
of ADAM12 WT and ADAM12 p.L792F proteins on the cell
surface (Fig. 3A (1:1.03 n=5)). Moreover, incubation at 37uC for
30 or 60 min showed similar levels and rates of internalization
between ADAM12 WT and ADAM12 p.L792F (Fig. 3A,B).
Internalization and subsequent intracellular localization of AD-
AM12 p.L792F was evaluated by immunofluorescent staining and
confocal microscopy. ADAM12 WT or ADAM12 p.L792F
expressing cells were labeled with the anti-ADAM12 antibody
6E6 at 4uC to detect only cell surface proteins. Cells were then
either fixed immediately (0 min) or incubated for 15 or 30 min at
37uC to allow protein internalization followed by fixation.
Previous publications [24,25] as well as our own unpublished
data (Stautz et al, manuscript in revision) suggests that ADAM12,
and possibly other ADAMs are internalized via the clathrin-
dependent pathway and that after initial internalization ADAM12
localizes to early endosomes. We therefore included clathrin heavy
chain (CHC) and early endosomal antigen 1 (EEA1) as markers in
these stainings, to evaluate if the ADAM12 p.L792F behaved
differently. At 0 min, both ADAM12 WT and ADAM12 p.L792F
displayed cell surface staining, confirming the presence of both
proteins at the cell surface (Fig. 3C, top row). After 15 or 30 min
incubation at 37uC, both WT ADAM12 and ADAM12 p.L792F
could be seen in punctate intracellular structures, and at all time-
points there was partial co-localization with EEA1 and CHC
(merged images, Fig. 3C), indicating that the same internalization
pathway(s) is/are employed, and that once internalized the
proteins localize similarly. After 15 min of incubation at 37uC,
both proteins localized to punctate structures mainly close to the
cell surface, whereas after 60 min of incubation at 37uC,
localization was predominantly perinuclear. Together these data
Figure 1. Schematic illustration of ADAM12 indicating the published breast cancer-associated mutations and the di-leucine motif
in the cytoplasmic tail. Schematic illustration of the domain organization of ADAM12. S: Signal peptide; Pro: Prodomain; Met: Metalloprotease
domain; Dis: Disintegrin domain; Cys: Cysteine-rich domain; EGF: EGF-like domain; TM: Transmembrane domain; Cyt: Cytoplasmic tail. Positions of the
three breast cancer-associated mutations are indicated and the amino acid sequence containing the di-leucine motif is shown.
doi:10.1371/journal.pone.0037628.g001
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PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37628Figure 2. Expression and processing of ADAM12 wild-type and p.L792F mutant. (A) ADAM12 p.L792F is expressed and processed similarly
to WT ADAM12. 293VnR cells were transiently transfected with increasing amounts of either ADAM12 WT or ADAM12 p.L792F. After 48 h cells were
lysed, total protein amounts were determined and proteins analyzed by SDS-PAGE and subsequent western blot with an anti-ADAM12 antibody. The
ADAM12 proform (proA12) is ,120 kDa and the mature form (matA12) is ,95 kDa (arrowheads). The membranes were re-probed with anti-actin
antibody to confirm equal loading. (B) Similar immunofluorescent staining of ADAM12 WT and p.L792F mutant. 293VnR cells were transiently
transfected with ADAM12 WT or ADAM12 p.L792F and after two days of incubation, seeded onto FBS coated coverslips. Cells were fixed in 4% PFA,
permeabilized in Triton X-100, labeled with ADAM12 monoclonal antibody 6E6 for 1 hour, and followed by staining with secondary antibody and
DAPI. Two representative images acquired using confocal laser-scanning microscopy are shown for each protein. White arrows indicate staining at
cell-cell junctions. Scale bar=10 mm. (C) 293VnR cells were transiently transfected with ADAM12-GFP WT or ADAM12-myc p.L792F and processed as
described in B, except that cells were labeled with anti-myc instead of anti-ADAM12 primary antibody. Scale bar=10 mm.
doi:10.1371/journal.pone.0037628.g002
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PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e37628Figure 3. ADAM12 p.L792F localizes to the cell surface and is internalized similarly to wild-type ADAM12. (A) Biotinylation of cell
surface ADAM12 WT or ADAM12 p.L792F. 293VnR cells, transiently transfected with ADAM12-GFP or ADAM12-GFP p.L792F were labeled with NHS-SS-
Biotin for 30 min at 4uC, with subsequent incubation at 4uC (controls) or at 37uC for indicated time points. Then, the cells were treated with reducing
reagent (glutathione) to remove non-internalized biotin from the cell surface (except for total biotinylation control lane 1). The control samples kept
at 4uC were included to ensure proper removal of cell surface biotin. Biotinylated proteins were precipitated with streptavidin-conjugated agarose
beads and subjected to western blotting with the appropriate antibodies. The ADAM12-GFP proform (proA12) is ,150 kDa and the mature form
(matA12) is ,130 kDa. Actin was used as a loading control. TCL: Total cell lysate. (B) Quantitative analysis of ADAM12 internalization where
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and ADAM p.L792F during internalization. We conclude that the
mutation did not obviously affect ADAM12 trafficking.
The p.L792F mutation does not alter ADAM12-mediated
cell proliferation or proteolytic activity
We evaluated two key potential biological consequences of the
p.L792F mutation. Since recent findings showed an effect of
ADAM12 on tumor cell proliferation [13], ADAM12 p.L792F was
tested for effects on cell proliferation. However, in analysis of cells
expressing WT or ADAM12 p.L792F by EdU incorporation, no
difference in the number of dividing cells was seen (Fig. 4A). Since
ADAM12 is a catalytically active ADAM, we investigated if the
p.L792F mutation affected ADAM12-mediated shedding of pro-
epidermal growth factor (proEGF). Cells expressing alkaline
phosphatase-tagged proEGF (AP-EGF) together with catalytically
inactive (CI) ADAM12, ADAM12 WT, or ADAM12 p.L792F
were tested for release of AP-EGF into the culture medium. All
proteins were expressed at similar levels (Fig. 4C) and both
ADAM12 WT and ADAM12 p.L792F showed increased shedding
of proEGF compared to CI ADAM12. However, ADAM12
p.L792F -mediated shedding did not differ from that of ADAM12
WT (Fig. 4B). Thus, based on these data, the p.L792F mutant has
no apparent functional impact in the assays employed.
In summary, we have investigated one of three previously
reported breast cancer-associated mutations in the metalloprotease
ADAM12, namely the intracellular p.L792F mutation. Despite the
affected residue being situated in a potential di-leucine trafficking
motif, evaluation of the mutant protein did not reveal any
detectable effects on expression, processing, trafficking or known
ADAM12 function, as compared to ADAM12 WT. This lack of a
functional effect is consistent with leucine 792 not being conserved
in human and mouse ADAM12, and indeed, few human ADAMs
contain di-leucine motifs (LL or LI), arguing against this being a
general trafficking signal for ADAM proteins. ADAM12 has a
second di-leucine motif upstream of the one currently investigated,
which is more conserved between species. Yet, this sequence
deviates more from consensus di-leucine trafficking motifs.
Interestingly, a non-consensus di-leucine motif is also found in
the related transmembrane MT1-MMP and this seems to be
important for protein glycosylation, rather than protein trafficking
[26]. However, no impact of the mutation on ADAM12
glycosylation was observed. Thus, based on the reported data,
we suggest that the p.L972F mutation in ADAM12 is likely a
passenger mutation and not a cancer causing driver mutation.
Methods
Unless otherwise stated, chemicals were purchased from Sigma-
Aldrich (St. Louis, MO, USA).
Antibodies
Mouse monoclonal antibody 6E6 directed against the disin-
tegrin and cysteine-rich domains of ADAM12 was previously
described [27]. Primary antibodies: ADAM12 Polyclonal Anti-
body (ProteinTech Group, Chicago, IL, USA), GFP antibody full-
length a.v. polyclonal antibody (Clontech, Mountain View, CA,
USA), mouse anti-actin and anti-myc monoclonal antibodies
(Millipore, Bedford, MA, USA), rabbit polyclonal anti-EEA1 and
anti-CHC antibodies (Abcam, Cambridge, UK). Secondary
antibodies for western blot were polyclonal goat anti-mouse
immunoglobulins/HRP and polyclonal goat anti-rabbit immuno-
globulins/HRP (Dako A/S, Glostrup, Denmark). Secondary
antibodies for immunofluorescent staining were Alexa FluorH
546 F(ab9)2 fragment of goat anti-mouse IgG and Alexa FluorH
546 F(ab9)2 fragment of goat anti-rabbit IgG (Invitrogen, Carlsbad,
CA, USA).
Cell culture
Human epithelial HEK293VnR cells stably expressing the
vitronectin receptor (avb3 integrins) (henceforth referred to as
293VnR) [28] were maintained in Dulbecco’s Modified Eagle
Medium (DMEM) with GlutaMAX
TM-I, supplemented with 10%
Fetal Bovine Serum (Hyclone, Perbio, Bonn, Germany).
Expression constructs
Mammalian expression constructs for full-length membrane-
bound human ADAM12 (ADAM12-L), human ADAM12 fused at
its C-terminus to green fluorescent protein (ADAM12-GFP) and
catalytically inactive (CI) ADAM12-GFP (E351Q mutation) were
previously described [29,30]. ADAM12-myc-His was made by
excision of ADAM12 cDNA from the pEGFP-N1 vector using
XhoI and BamHI restriction enzymes and ligation into the
corresponding pcDNA3.1/myc-His B vector (Invitrogen). The
leucine to phenylalanine (p.L972F) mutation in ADAM12,
ADAM12-myc and ADAM12-GFP were made by Mutagenex,
Innovative Mutagenesis and Directed Evolution (www.mutagenex.
com). ProEGF fused to alkaline phosphatase (AP) in the pRC/
CMV expression vector (proEGF-AP) was kindly provided by Dr.
S. Higashiyama, Ehime University Graduate School of Medicine,
Ehime, Japan.
Transfections
293VnR cells were transfected using OPTI-MEMH I Reduced
Serum Medium (Gibco, Invitrogen) and FuGENEH 6 Transfection
Reagent (Roche Applied Science, Hvidovre, Denmark) according
to manufacturer’s instructions. Experiments were carried out 48 h
after transfection.
Cell surface biotinylation assay
All reagents were kept at 4uC and biotinylation with membrane
impermeable reagents was carried out at 4uC to selectively label
cell surface proteins. Transiently transfected 293VnR cells were
preincubated at 4uC for 15 min to stop ongoing internalization,
washed in cold phosphate buffered saline (PBS, Invitrogen), and
incubated for 30 min at 4uC with 0.05 mg/ml EZ-Link
TM Sulfo-
NHS-SS-Biotin (Pierce, Thermo Scientific, Rockford, IL, USA) in
cold PBS. Biotinylation was quenched by three washes in 100 mM
glycine (AppliChem, Darmstadt, Germany) in cold PBS and once
internalized ADAM12-GFP at 30 or 60 min at 37uC were calculated as fold-change compared to total biotinylated ADAM12-GFP for each WT or
mutant sample. The data are shown as +/2 standard error of the mean (SEM) (n=5 independent experiments); ‘‘ns.’’ indicates no statistical difference
(p.0.05, two-tailed unpaired t-test). (C) ADAM12 WT or ADAM12 p.L792F internalization and co-localization with the early endosomal marker (EEA1)
and clathrin heavy chain (CHC). The images show immunofluorescent staining and confocal laser-scanning microscopy of 293VnR cells transiently
transfected with ADAM12 WT or the p.L792F mutant and seeded onto FBS-coated coverslips. Cells were labeled with ADAM12 monoclonal antibody
6E6 for 1 hour at 4uC, washed, and incubated in culture medium for 15 min or 30 min, followed by fixation and permeabilization. Cells were then
stained with an EEA1 antibody (top three panels) or CHC antibody (bottom three panels) for 1 h at RT and subsequently with appropriate secondary
antibodies and DAPI (n=2). Merged images show partial co-localization of ADAM12 and EEA1 or CHC. Scale bar=10 mm.
doi:10.1371/journal.pone.0037628.g003
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added to the cells, which, except for the controls were transferred
to 37uC for the time points required for each experiment. After
incubation, cells were washed once in cold PBS and non-
internalized cell surface biotin was removed by washing
3610 min in stripping buffer (50 mM L-Glutathione, 75 mM
NaCl, 75 mM NaOH, 1% (w/v) bovine serum albumin (BSA) and
10 mM ethylenediaminetetraacetic acid (EDTA) pH 8.0). Finally,
cells were washed three times in cold PBS and lysed in
radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris
pH 7.4; 150 mM NaCl; 0.1% sodium dodecyl sulphate (SDS);
1% Triton X-100 0.5% sodium deoxycholate; 1 mM EDTA, and
complete EDTA-free inhibitor cocktail (Roche)). Cell lysates were
cleared by centrifugation for 20 min at 16,000 g and supernatants
were incubated with streptavidin-agarose (Sigma) for 2 h at 4uC.
Beads were washed three times in RIPA buffer and bound proteins
were released by heating for 5 min at 95uCi n2 6 SDS-PAGE
sample buffer (0.0625 M Tris pH 6.8, 20% glycerol, 2% SDS,
0.01% bromophenol blue, 5% 2-mercaptoethanol). Samples were
analyzed by western blot.
Western blotting
Total cell lysates and streptavidin affinity-isolated proteins were
subjected to standard 7.5% or 10% reducing SDS-PAGE and
transferred to Hybond-ECL nitrocellulose membranes (GE
Healthcare). The membranes were incubated with the indicated
primary antibodies and subsequently with the appropriate
horseradish peroxidase (HRP)-conjugated secondary antibody.
The EZ ECL Chemiluminescence Detection Kit for HRP
(Biological Industries Ltd, Kibbutz Beit Haemek, Israel) was used
to detect antibody binding and images were acquired using the
LAS3000 Imager (Fujifilm), or using Hyperfilm ECL high
performance chemiluminescence film (GE Healthcare) and a
Valsoe X-Ray developer (Ferrania, Valsoe X-ray, Hoejbjerg,
Denmark).
Densitometric analysis of western blots
The TotalLab TL100 software (TotalLab Limited) was used to
perform densitometric analysis. Briefly, total cell surface biotiny-
lated ADAM12, biotinylated endocytosed ADAM12, and AD-
AM12 in the total cell lysates (TCL/input) were quantified in
unsaturated (brief exposure) western blot images (mature AD-
AM12 form only). Levels of ADAM12 in the pull-down assay were
adjusted to ADAM12 levels in the total cell lysate for each WT or
mutant protein and then the fold-endocytosed ADAM12 was
calculated from the total cell surface biotinylated ADAM12. In
each case, total cell surface biotinylated ADAM12 was set to 1.
Immunofluorescence and confocal microscopy
Transiently transfected 293VnR cells were plated on FBS-
coated coverslips (Menzel, Braunschweig, Germany) and allowed
to attach and spread for 24 h. Cells were then either fixed directly
in 4% paraformaldehyde (PFA, Merck, Darmstadt, Germany) at
room temperature (RT) (for permeabilized cell staining) or, for cell
surface staining, preincubated at 4uC for 15 min to stop ongoing
internalization, and subsequently incubated with 6E6 antibody
diluted in 1% BSA in PBS for 1 h at 4uC. Cells were washed in
cold PBS and cold DMEM was added to the cells, which, except
for the controls, were transferred to 37uC at the time points
indicated. After incubation, cells were fixed in fresh 4% PFA at
Figure 4. ADAM12 p.L792F does not affect cell proliferation or
EGF shedding. (A) Comparable proliferation of ADAM12 WT and
ADAM12 p.L792F expressing cells. 293VnR cells transiently transfected
with ADAM12-GFP or ADAM12-GFP p.L792F were plated on FBS-coated
coverslips in triplicates. Proliferating cells were stained with Edu. Four
images were taken from each triplicate and EdU- and GFP-positive cells
were calculated as percentage of total cells (DAPI staining). The data are
shown as +/2 standard error of the mean (SEM) (n=2 independent
experiments performed in triplicates); ‘‘ns.’’ indicates no statistical
difference (p.0.05, two-tailed unpaired t-test). (B) ADAM12 p.L792F
does not affect ADAM12-mediated proEGF shedding. 293VnR cells were
transiently transfected with alkaline phosphatase (AP)-tagged proEGF
together with ADAM12-GFP WT, CI ADAM12-GFP, or ADAM12 p.L792F
(p.L792F). EGF-shedding was calculated from the ratio of AP activity in
the cell media to total AP activity in the media and corresponding cell
lysate, corrected for background (sample without AP substrate) (n=2
independent experiments performed in triplicate). * indicates a
statistically significant difference (p,0.0001, two-tailed unpaired t-test)
and ‘‘ns.’’ indicates no statistical difference (p.0.05). (C) Representative
western blot of protein expression control from experiment in (B).
Transfected 293VnR cells were lysed in RIPA buffer and analyzed by
western blot with the appropriate antibodies. Note the reduction in the
upper band of AP-EGF, indicating shedding of proEGF-AP from the cell
surface. Actin was used as a loading control.
doi:10.1371/journal.pone.0037628.g004
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groups were quenched with 0.1 M NH4Cl/PBS and cells were
blocked with 5% BSA/PBS. For co-staining with 6E6 and EEA1,
cells were incubated with primary antibody diluted in 1% BSA in
PBS for 1 h at RT. All cells were stained with the appropriate
Alexa 488 or Alexa 546 secondary antibodies and 49,6-diamidino-
2-phenylindole (DAPI) (Invitrogen) in 1% BSA/PBS for 1 h at
RT. Coverslips were mounted on Super Premium Microscope
Slides (VWR, Albertslund, Denmark) using DAKOH Faramount
Aqueous Mounting Medium (Dako). Micrographs were acquired
on a confocal microscope (Axiovert 200 M LSM 520; Carl Zeiss,
Inc.) using a 636 C-Apochromat objective with a numerical
aperture of 1.2 in H2O. Micrographs were taken at room
temperature. The images were processed using the LSM Image
Browser software (Carl Zeiss, Inc.).
Cell proliferation assay
293VnR cells transiently transfected with ADAM12-GFP WT
or ADAM12-GFP p.L972F were plated in triplicate on FBS-coated
coverslips and allowed to attach and spread for 24 h. Proliferating
cells were stained using the Click-iTH EdU Alexa FluorH 594
Imaging Kit (Invitrogen) according to manufacturer’s instructions
and nuclei were stained using DAPI. Four images from each
triplicate experiment were acquired using the Zeiss Axiovert
200 M ApoTome (Carl Zeiss, Inc.) with Axiovision software and
analyzed with the Metamorph software. Nuclei positive for both
EdU and GFP were calculated as percentage of total nuclei (DAPI
stain).
Shedding assay
293VnR cells were transiently transfected with proEGF-AP
together with WT ADAM12-GFP, catalytically inactive AD-
AM12-GFP, or ADAM12-GFP p.L972F. Forty-eight hours after
transfection, each transfection was split into four wells in a 24-well
plate. The next day, one well of each transfection was washed 36
in PBS and lyzed in RIPA buffer to serve as an expression control
in analysis by Western blot. The remaining wells (triplicates) were
washed twice with PBS, followed by 2 h incubation with fresh
serum free medium. For photometric quantitation of proEGF-AP
shedding, cell-conditioned medium was harvested and the cell
layer lysed in 1% Triton X-100 in PBS. Conditioned serum free
medium or cell lysate (50 ml) from each well was mixed with 50 ml
of a 2 mg/ml solution of the alkaline phosphatase substrate 4-
nitrophenyl (Sigma), with each well assayed in duplicate in a 96-
well plate. Alkaline phosphatase activity was quantified as
absorbance at 405 nm as a function of time, and the fold-change
in EGF-shedding activity was calculated as alkaline phosphatase
activity in the conditioned media divided by total alkaline
phosphatase activity in the media plus the corresponding cell
lysate. CI ADAM12 was set as 1 and fold shedding by the
corresponding ADAM12 WT and mutant was calculated.
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